Patents Assigned to MandalMed, Inc.
  • Methods and compositions for preventing and treating damage to the heart
    Patent number: 11179439
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: November 23, 2021
    Assignees: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. John, Meenakshi Gaur, Matthew L. Springer, Xiaoyin Wang
  • METHODS AND COMPOSITIONS FOR PREVENTING, TREATING, AND REVERSING LIVER FIBROSIS
    Publication number: 20210353715
    Abstract: Methods of reducing, treating, or reversing liver fibrosis in a subject in need thereof comprising administering Galectin-3C, are provided. Also provided are Galectin-3C fusion proteins with increased stability.
    Type: Application
    Filed: September 19, 2019
    Publication date: November 18, 2021
    Applicant: MandalMed, Inc.
    Inventors: Constance M. JOHN, Khalil MOUNZIH
  • Proliferative primary human Sertoli cell cultures and their applications
    Patent number: 10851348
    Abstract: Technology for the isolation and propagation of primary human Sertoli cells from normal testes tissue, including cultures of proliferative primary human Sertoli cells for research and clinical applications, and a pharmaceutical composition for cell therapy, ex vivo gene therapy, and for the reduction of autoimmune, allograft, and xenograft immune reactions.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 1, 2020
    Assignee: MANDALMED, INC.
    Inventors: Constance M. John, Alpa Mahuvakar
  • METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING DAMAGE TO THE HEART
    Publication number: 20200246427
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Application
    Filed: June 18, 2019
    Publication date: August 6, 2020
    Applicants: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. JOHN, Meenakshi GAUR, Matthew L. SPRINGER, Xiaoyin WANG
  • Methods and compositions for preventing and treating damage to the heart
    Patent number: 10369195
    Abstract: Provided herein are methods and compositions for preventing and treating damage to the heart subsequent to myocardial infarction (MI) resulting from harmful fibrotic remodeling, thereby improving cardiac function and reducing mortality from subsequent heart failure.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: August 6, 2019
    Assignees: MandalMed, Inc., The Regents of the University of California
    Inventors: Constance M. John, Meenakshi Gaur, Matthew L. Springer, Xiaoyin Wang
  • Galectin-3C combination therapy for human cancer
    Patent number: 9272014
    Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: March 1, 2016
    Assignees: Texas Tech University System, MandalMed, Inc.
    Inventors: Maurizio Chiriva-Internati, Everardo Cobos, Constance John